Genetic diversity of NS3 protease from Brazilian HCV isolates and possible implications for therapy with direct-acting antiviral drugs

Genetic diversity of NS3 protease from Brazilian HCV isolates and possible implications for therapy with direct-acting antiviral drugs

The hepatitis C virus (HCV) NS3 protease has been one of the molecular targets of new therapeutic approaches. Its genomic sequence variability in Brazilian HCV isolates is poorly documented. To obtain more information on the magnitude of its genetic diversity, 114 Brazilian HCV samples were sequence...

Full description

Bibliographic Details
Main Authors:	Allan Peres-da-Silva, Adilson José de Almeida, Elisabeth Lampe
Format:	Article
Language:	English
Published:	Fundação Oswaldo Cruz (FIOCRUZ) 2012-03-01
Series:	Memorias do Instituto Oswaldo Cruz
Subjects:	genetic diversity NS3 protease hepatitis C virus direct-acting antiviral agents
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762012000200016&lng=en&tlng=en

Similar Items

HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral Therapy
by: Kazuaki Chayama, et al.
Published: (2015-10-01)

Detection of anti-protease inhibitors resistance mutations in HCV strains infecting treatment-naïve chronic patients from Romania
by: Dinu Sorin, et al.
Published: (2018-10-01)

Protease inhibitors for the treatment of hepatitis C virus infection
by: de Leuw, Philipp, et al.
Published: (2017-11-01)

The flavivirus NS2B–NS3 protease–helicase as a target for antiviral drug development
by: Luo, Dahai, et al.
Published: (2016)

Direct-Acting Antivirals for HCV Treatment in Decompensated Liver Cirrhosis Patients: A Systematic Review and Meta-Analysis
by: JiHyun An, et al.
Published: (2022-09-01)

Effects of NS2B-NS3 protease and furin inhibition on West Nile and Dengue virus replication
by: Jenny Kouretova, et al.
Published: (2017-01-01)

Serum autotaxin levels in responders to HCV treatment by direct-acting antivirals
by: Nancy Abdel Fattah Ahmed, et al.
Published: (2020-08-01)

The Future of HCV Therapy: NS4B as an Antiviral Target
by: Hadas Dvory-Sobol, et al.
Published: (2010-11-01)

Effects of the Q80K Polymorphism on the Physicochemical Properties of Hepatitis C Virus Subtype 1a NS3 Protease
by: Allan Peres-da-Silva, et al.
Published: (2019-07-01)

Potential Role of Flavivirus NS2B-NS3 Proteases in Viral Pathogenesis and Anti-flavivirus Drug Discovery Employing Animal Cells and Models: A Review
by: Abdul Wahaab, et al.
Published: (2021-12-01)

Phosphonate inhibitors of West Nile virus NS2B/NS3 protease
by: Marcin Skoreński, et al.
Published: (2019-01-01)

Long term changes in thrombocytopenia and leucopenia after HCV eradication with direct-acting antivirals
by: Kazuto Tajiri, et al.
Published: (2023-05-01)

Structure-Based Virtual Screening: Identification of a Novel NS2B-NS3 Protease Inhibitor with Potent Antiviral Activity against Zika and Dengue Viruses
by: Hye Jin Shin, et al.
Published: (2021-03-01)

Liver Fibrosis Regression and Associated Factors in HCV Patients Treated with Direct-Acting Antiviral Agents
by: Naim Abu-Freha, et al.
Published: (2023-09-01)

Characterization of NS5A and NS5B Resistance-Associated Substitutions from Genotype 1 Hepatitis C Virus Infected Patients in a Portuguese Cohort
by: Ruben Brandão, et al.
Published: (2018-04-01)

Design, Synthesis, and in-vitro Protease Inhibition Assay of Linear Pentapeptides as Potential Dengue Virus NS2B/NS3 Protease Inhibitors
by: NADEEM ABDALRAZAQ, et al.
Published: (2022-04-01)

Allosteric Inhibitors of Zika Virus NS2B-NS3 Protease Targeting Protease in “Super-Open” Conformation
by: Ittipat Meewan, et al.
Published: (2023-04-01)

Dynamic interactions of post cleaved NS2B cofactor and NS3 protease identified by integrative structural approaches
by: Quek, Jun-Ping, et al.
Published: (2022)

Development of a rapid phenotypic test for HCV protease inhibitors with potential use in clinical decisions
by: Luciana Santos Pessoa, et al.

Structures of Zika virus NS2B-NS3 protease in complex with peptidomimetic inhibitors
by: Phoo, Wint Wint, et al.
Published: (2019)

Variability and resistance mutations in the hepatitis C virus NS3 protease in patients not treated with protease inhibitors
by: Luciana Bonome Zeminian, et al.
Published: (2013-02-01)

Variability and resistance mutations in the hepatitis C virus NS3 protease in patients not treated with protease inhibitors
by: Luciana Bonome Zeminian, et al.
Published: (2013-02-01)

Dynamic Interactions of Post Cleaved NS2B Cofactor and NS3 Protease Identified by Integrative Structural Approaches
by: Jun-Ping Quek, et al.
Published: (2022-06-01)

Inhibition of dengue NS2B-NS3 protease and viral replication in Vero cells by recombinant retrocyclin-1
by: Rothan Hussin A, et al.
Published: (2012-11-01)

New treatment of hepatitis C (Direct Acting Antiviral)
by: Mohsen Akhondi-Meybodi
Published: (2019-10-01)

In Vitro Evaluation of Novel Inhibitors against the NS2B-NS3 Protease of Dengue Fever Virus Type 4
by: Thi Thanh Hanh Nguyen, et al.
Published: (2013-12-01)

An Antiviral Peptide from <i>Alopecosa nagpag</i> Spider Targets NS2B–NS3 Protease of Flaviviruses
by: Mengyao Ji, et al.
Published: (2019-10-01)

Hepatic decompensation associated with an interferon-free antiviral therapy in patients with HCV-cirrhosis
by: S N Batskikh, et al.
Published: (2018-11-01)

Norovirus Protease Structure and Antivirals Development
by: Boyang Zhao, et al.
Published: (2021-10-01)

Effects of HCV Clearance with Direct-Acting Antivirals (DAAs) on Liver Stiffness, Liver Fibrosis Stage and Metabolic/Cellular Parameters
by: Joana Ferreira, et al.
Published: (2024-02-01)

HCV-Specific T Cell Responses During and After Chronic HCV Infection
by: Hendrik Luxenburger, et al.
Published: (2018-11-01)

Resistance mutations of NS3 and NS5b in treatment-naïve patients infected with hepatitis C virus in Santa Catarina and Rio Grande do Sul states, Brazil
by: Elisabete Andrade, et al.
Published: (2020-02-01)

Prevalence of Naturally-Occurring NS5A and NS5B Resistance-Associated Substitutions in Iranian Patients With Chronic Hepatitis C Infection
by: Pooneh Rahimi, et al.
Published: (2021-01-01)

Efficacy and safety of direct-acting antivirals for HCV in patients with extrahepatic malignancies: real-life experience
by: Mira Atef, et al.
Published: (2022-09-01)

Computational design and in vitro assay of lantadene-based novel inhibitors of NS3 protease of dengue virus
by: Mujwar Somdutt, et al.
Published: (2024-03-01)

Effect of Successful Direct Acting Antivirals Therapy on Liver Stiffness in Patients with Chronic HCV Infection
by: Ibrahim Anam Ezzelregal, et al.
Published: (2020-10-01)

HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents
by: Andrea Angeletti, et al.
Published: (2019-02-01)

Effects of Lower Temperature on Expression and Biochemical Characteristics of HCV NS3 Antigen Recombinant Protein
by: Chen-Ji Huang, et al.
Published: (2021-10-01)

Dataset on biochemical inhibiting activities of selected phytochemicals in Azadirachta indica L as potential NS2B–NS3 proteases inhibitors
by: Abel Kolawole Oyebamiji, et al.
Published: (2023-06-01)

Synthesis and biological activity of imidazole phenazine derivatives as potential inhibitors for NS2B-NS3 dengue protease
by: Nur Sarah Dyana Khalili, et al.
Published: (2024-01-01)